Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients

Last updated: August 27, 2021
Sponsor: American University of Beirut Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Multiple Sclerosis

Neurologic Disorders

Scar Tissue

Treatment

N/A

Clinical Study ID

NCT03610139
BIO-2017-0395
  • Ages > 18
  • All Genders

Study Summary

This is a longitudinal single blind randomized trial to test the effects of high compared to low dose vitamin D3 supplementation on cognitive performance at 6 and 12 months, and MRI measures of 12 months duration. A cognitive assessment battery will be administered at baseline, 6 and 12 months. Related clinical data and information on depression and anxiety, lifestyle, and food sources of vitamin D and sun exposure among other variables will also be collected.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Signed informed consent form
  • Males/ Females
  • Age ≥ 18 years old
  • Have a definite diagnosis of RRMS as per the revised McDonald 2010 or CIS.
  • Untreated or on any MS therapy
  • Showed no clinical evidence of relapses during the past month and disease duration notgreater than 10 years.
  • Subjects who have a serum vitamin D level below 25 ng/ml

Exclusion

Exclusion Criteria:

  • All subjects using drugs associated with hypercalcemia.
  • Pregnant and with history of primary hyper PTH.
  • Subjects with hypercalcemia, renal dysfunction, malignancy, or granulomatous disease,dementia, traumatic brain injury, diagnosis of epilepsy or history of seizure,psychiatric disease other than anxiety and depression, or are found to be suicidal onscreening, or taking psychoactive medications other than antidepressants
  • Subjects who have a serum vitamin D level above 25 ng/ml
  • Subjects who have not done an MRI scan up to 3 months before or after the baselinevisit.
  • Subjects who have a history of kidney stones
  • Subjects with malabsorption
  • Individuals with history of alcohol abuse/dependence and/or substanceuse/abuse/dependence will also be excluded from the study. Men who consume more than 15 drinks per week and women who consume more than eight drinks per week will beconsidered excessive alcohol consumers and will be excluded from the study.

Study Design

Total Participants: 162
Study Start date:
May 21, 2018
Estimated Completion Date:
December 31, 2022

Study Description

Background: Multiple Sclerosis is strongly associated with low serum 25 hydroxy-vitamin-D (25(OH)D) and impaired cognitive performance. In our previous research, participants with low serum 25OHD levels showed significant improvements in visuo-spatial memory delayed recall after 3 months of vitamin D3 supplementation. In addition, serum 25(OH)D was significantly associated with this memory function at baseline and at 3 months. Therefore, the aim of this proposed study is 1) to evaluate the long-term effects 6 and 12 months of high (50,000 IU weekly then 10,000 IU weekly) compared to low dose (800 IU daily) vitamin D3 replacement on cognitive function in MS, and 2) to correlate it with the MRI brain measurements of the hippocampus and the frontal cortex volumes, as well as brain parenchymal fraction, and cerebellum. The investigators will then explore these MRI measures in MS patients with deficient 25(OH)D levels at baseline and at 12 months, and correlate it with their cognitive performance.

Methods: This is a longitudinal single blind randomized trial to test the effects of high compared to low dose vitamin D3 supplementation on cognitive performance at 6 and 12 months, and MRI measures of 12 months duration. A cognitive assessment battery, comprised of the Montreal Cognitive Assessment (only at baseline), Stroop, Symbol Digit Modalities Test, Brief Visual Memory Test, and Verbal Memory Test in Arabic, will be administered at baseline, 6 and 12 months. Related clinical data and information on depression and anxiety, lifestyle, and food sources of vitamin D and sun exposure among other variables will also be collected.

Expected results: MS patients with serum 25(OH)D deficiency who receive high dose vitamin D3 supplementation will demonstrate decreased cognitive impairment at 6 and 12 months post supplementation when compared to those who received low vitamin D3 dose and to their pre-supplementation status. The MRI findings are expected to be associated with cognitive performance at baseline, and serum 25(OH)D levels at baseline, and 12 months.

Connect with a study center

  • Nehme & Therese Tohme Multiple Sclerosis Center

    Beirut, 1107 2020
    Lebanon

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.